Professor Phillip Robinson

Professor
Medicine, Children's Medical Research Institute

C29 - Children's Hospital Westmead
The University of Sydney
NSW 2006 Australia

T: 02 8865 2915
F: 02 9687 2120
E:

Curriculum vitae

Biographical details

Phil has a B.Sci. (Hons) in Biochemistry from Sydney University and in 1984 he completed a PhD in Medical Biochemistry at the University of Newcastle. After postdoctoral studies at the National Institutes of Health (NIH, USA), Merrell Dow Research Institute Cincinnati, and St. Vincent's Institute of Medical Research Melbourne, he became Principal Hospital Scientist at the John Hunter Hospital Newcastle. He took up his present position as Head of the Cell Signalling Unit at the Children’s Medical Research Institute (CMRI) Sydney in 1996 and is also a Professor in Medicine at the Universities of Sydney and Newcastle, and is one of only ~70 Australian scientists holding a Principal Research Fellowship from the NHMRC. He leads a team of 21 scientists, postdocs and graduate students.

Research interests

His research program focuses on understanding the molecular mechanisms of synaptic transmission in the nervous system. His work brings together cell signalling with protein chemistry and medicinal chemistries to: a) understand the basic science of nerve communication and b) develop drugs to control diseases of nerve terminals like epilepsy. Nerve communication involves neurotransmitter release at contact points between nerves – synapses. It occurs from small storage vesicles, synaptic vesicles, which accumulate at synapses. They must be recycled locally or synaptic transmission stops, resulting in paralysis. The main focus is on proteins called the dynamins, which are self-assembling molecular machines acting in many intracellular functions. Dynamin can self-assemble as a helix at the neck of newly forming synaptic vesicles to cut it free into the cell a process called endocytosis. There are three dynamin genes: dynI (neuron specific), dynII (ubiquitously expressed) and dynIII (low levels in neurons and testes) and dynII mutations cause Charcot-Marie Tooth neurodegeneration, the muscle disease Centronuclear Myopathy and childhood leukaemia.


Phil and his team have made many discoveries about the molecular mechanisms of endocytosis at the synapse. His work revealed that synaptic vesicle endocytosis is a highly regulated process in neurons, triggered by protein dephosphorylation. He uses mass spectrometry for phosphoproteomics to identify all phosphosites in all endocytic proteins and to rank them by abundance and physiological relevance. By working together with the Medicinal Chemist, Adam McCluskey, at the University of Newcastle they have utilised the new knowledge to develop potential new drugs. This represents part of an overall strategy to develop dynamin and endocytosis inhibitors: a) as tools for medical researchers to solve significant biological problems, and b) as potential candidate therapeutics for human disease indications in which harnessing endocytosis pathways may alleviate disease symptoms for epilepsy, cancer, infectious diseases and chronic kidney disease.

Current national competitive grants*

2012

The role of clathrin in the spindle assembly checkpoint and as an anti-cancer target
Chircop M, Robinson P, McCluskey A, Sakoff J
NHMRC Project Grants ($629,685 over 3 years)

Mechanism of action of dynamin ring stabilizer compounds controlling the actin cytoskeleton
Robinson P, McCluskey A
NHMRC Project Grants ($637,020 over 3 years)

* Grants administered through the University of Sydney